Pyruvate kinase M2 regulates homologous recombination-mediated DNA double-strand break repair. by Sizemore, Steven T et al.
UC Riverside
UC Riverside Previously Published Works
Title



















eScholarship.org Powered by the California Digital Library
University of California
ARTICLE OPEN
Pyruvate kinase M2 regulates homologous recombination-
mediated DNA double-strand break repair
Steven T. Sizemore 1, Manchao Zhang2, Ju Hwan Cho1, Gina M. Sizemore3, Brian Hurwitz4, Balveen Kaur1,4, Norman L. Lehman5,
Michael C. Ostrowski3, Pierre A. Robe6,7, Weili Miao8, Yinsheng Wang8, Arnab Chakravarti1 and Fen Xia2
Resistance to genotoxic therapies is a primary cause of treatment failure and tumor recurrence. The underlying mechanisms that
activate the DNA damage response (DDR) and allow cancer cells to escape the lethal effects of genotoxic therapies remain unclear.
Here, we uncover an unexpected mechanism through which pyruvate kinase M2 (PKM2), the highly expressed PK isoform in cancer
cells and a master regulator of cancer metabolic reprogramming, integrates with the DDR to directly promote DNA double-strand
break (DSB) repair. In response to ionizing radiation and oxidative stress, ATM phosphorylates PKM2 at T328 resulting in its nuclear
accumulation. pT328-PKM2 is required and sufficient to promote homologous recombination (HR)-mediated DNA DSB repair
through phosphorylation of CtBP-interacting protein (CtIP) on T126 to increase CtIP’s recruitment at DSBs and resection of DNA
ends. Disruption of the ATM-PKM2-CtIP axis sensitizes cancer cells to a variety of DNA-damaging agents and PARP1 inhibition.
Furthermore, increased nuclear pT328-PKM2 level is associated with significantly worse survival in glioblastoma patients.
Combined, these data advocate the use of PKM2-targeting strategies as a means to not only disrupt cancer metabolism but also
inhibit an important mechanism of resistance to genotoxic therapies.
Cell Research (2018) 28:1090–1102; https://doi.org/10.1038/s41422-018-0086-7
INTRODUCTION
Resistance to genotoxic therapies, such as radiation and DNA-
damaging chemotherapeutics, is the primary cause of treatment
failure for many cancers. Double-strand breaks (DSBs) account for
the majority of the cytotoxicity associated with these treatments
and cellular response to genotoxic stress is ultimately determined
by repair of these lethal lesions. There are two primary pathways,
non-homologous end-joining (NHEJ) and homologous recombina-
tion (HR), to repair DNA DSBs. NHEJ takes place during all phases
of the cell cycle and is the predominant repair pathway during the
G1/G0 phase while HR repair primarily occurs during S phase.1,2
The serine/threonine kinase ataxia telangiectasia mutated (ATM)
is a key protein kinase that regulates multiple DDR processes
including DNA repair through the NHEJ and HR pathways.3 While
both the NHEJ and HR pathways are involved in cancer resistance
to genotoxic therapies, the HR repair pathway is particularly
critical in highly proliferative cancer cells. HR-mediated repair
utilizes intact homologous DNA sequences as templates to repair
DSBs with high fidelity. CtBP-interacting protein (CtIP) is a key rate-
limiting component of HR repair that interacts with the Mre11/
Rad50/Nbs1 (MRN) complex to promote DSB end-resection,
generation of ssDNA tails, and initiation of DSB repair.4 While
ATM and CtIP are indisputably important mediators of cancer
resistance to genotoxic agents, efforts to reduce cancer cell
resistance to therapy via directly targeting these molecules are
inherently limited given their essential functions in normal cells.
Identification of ATM substrates and/or CtIP effectors that are vital
to DNA DSB repair in cancer cells but are dispensable to repair in
normal cells could provide essential tools to combat treatment
resistance.
Metabolic reprogramming, including aerobic glycolysis, known
as the Warburg effect, is one of the most obvious and universal
differences between cancer cells and their cognate normal cell of
origin. While most of the key enzymes involved in glycolysis are
shared between cancer and normal cells, overexpression of
pyruvate kinase M2 (PKM2) in cancer cells drives the Warburg
effect.5 A growing body of evidence suggests that PKM2 supports
cancer cell metabolism and growth not only through its pyruvate
kinase activity in the cytosol, but also through its more recently
discovered nuclear function as transcriptional coactivator. Nuclear
PKM2 regulates expression of genes encoding glucose transporter
1 (GLUT1/SLC2A1) and lactate dehydrogenase A (LDHA)5 in a
positive feed-forward manner to further support glycolytic
metabolism. A number of post-translational modifications, includ-
ing phosphorylation by ERK1/2,5,6 have been identified to regulate
PKM2’s cytoplasmic/nuclear distribution.
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Emerging evidence indicates that coordination between
glucose metabolism and DNA DSB repair is important for
sustained cancer cell proliferation and survival from intracellular
oxidative stress, and genotoxic treatment.7,8 However, the under-
lying mechanisms that enable crosstalk between these processes
remain to be elucidated. In this study, we demonstrate a novel
mechanism through which PKM2 directly regulates DSB repair to
provide resistance to DNA damage. PKM2 phosphorylates CtIP at
T126 to activate CtIP’s end-resection function and increase HR-
mediated DSB repair. ATM is identified as the upstream mediator
that phosphorylates nuclear PKM2 at T328 following DNA damage.
Phosphorylation of T328 in the nucleus is required and sufficient
to increase PKM2’s nuclear accumulation and its interaction with
and phosphorylation of CtIP. Furthermore, the nuclear level of
T328-phosphorylated PKM2, a readout of ATM-PKM2-CtIP pathway
activity, is prognostic of poor overall survival in glioblastoma
patients. Our findings reveal that PKM2, a key controller of cancer
metabolic reprogramming, directly regulates DNA repair and
advocate PKM2-targeted therapies to combat treatment resis-
tance and improve cancer patient outcomes.
RESULTS
PKM2 is a critical mediator of cellular resistance to DNA-damaging
treatment
To investigate the role of PKM2 in cancer cell resistance to DNA-
damaging therapies, we stably knocked down PKM2 in the human
glioblastoma multiforme (GBM) U87 cell line, which expresses high
endogenous levels of PKM29 (Supplementary information, Fig.
S1a), and subjected these cells to ionizing radiation (IR). While
PKM2 knockdown had no effect on cell cycle distribution (data not
shown), it resulted in a > 10-fold increase in radiation sensitivity at
doses of 4 Gy or above (P < 0.005 at 8 Gy, Fig. 1a). Increased
sensitivity to radiation following PKM2 knockdown was confirmed
by transient knockdown of PKM2 in U87, T98G, and U251 GBM cell
lines (Fig. 1b, Supplementary information, Fig. S1b and c), as well
as in H1299 (non-small cell lung cancer; data not shown) and
HT1904 (derived from the HT1080 fibrosarcoma line; data not
shown). In contrast, knockdown of PKM1, the primary pyruvate
kinase isoform expressed in normal brain (Supplementary
information, Fig. S1a, e, f), did not sensitize U87 cells to radiation
(Fig. 1b) nor did PKM1 knockdown sensitize normal human
astrocytes to radiation (data not shown).
Next, we examined the role of PKM2 in radiation resistance
in vivo by monitoring the growth of subcutaneous U87 tumors
expressing shCtrl or shPKM2 in nude mice. The combination of
PKM2 knockdown and radiation (2 Gy × 5 d) inhibited tumor
growth significantly more than either treatment alone, indicating
a critical role for PKM2 in treatment resistance in vivo (Fig. 1c).
We then assessed the role of PKM2 in treatment resistance
using a more clinically relevant intracranial tumor model
generated with the human GBM U87/EGFRvIII cell line, which
expresses a truncated, constitutively active EGFR mutant fre-
quently expressed in GBM (Fig. 1d, e; Supplementary information,
Fig. S1d, f). Like actual human GBM tumors (Supplementary
information, Fig. S1e), the mouse intracranial U87/EGFRvIII tumor
model exhibits rapid proliferation as evidenced by Ki-67 staining
(Fig. 1d) and expresses high levels of PKM2 and little PKM1 while,
conversely, the surrounding normal brain tissue expresses high
levels of PKM1 and little PKM2 (Supplementary information,
Fig. S1f). Knockdown of PKM2 alone or whole brain irradiation (4
Gy × 3 d) alone significantly improved mean survival time by 7.1
and 4.65 days, respectively, relative to untreated control mice
(Fig. 1e). Importantly, silencing PKM2 in combination with
radiation treatment increased the survival time to more than
double (16.4 additional days compared to untreated control mice)
that attributed to silencing PKM2 alone (7.1 additional days) or
radiation alone (4.65 additional days) (Fig. 1e). Combined, these
results suggest that PKM2 significantly contributes to the
resistance of cancer cells to DNA-damaging treatment in vitro
and in vivo.
Radiation with or without temozolomide is standard adjuvant
treatment for GBM.10 We hypothesized that, as an important
mechanism of resistance to DNA-damaging therapies, elevated
PKM2 expression should be associated with decreased overall
survival in GBM patients. To test this hypothesis, we selected
patients in the large TCGA GBM cohort (TCGA Research Network:
http://cancergenome.nih.gov/) that received radiation treatment
as well as patients that received no treatment and stratified these
populations by PKM expression. The probe used in this dataset
recognizes the PKM transcript which is preferentially spliced in
GBM to yield the PKM2 isoform.11 High (upper 10th percentile)
PKM expression was significantly prognostic of reduced overall
survival in patients that received genotoxic treatment (log rank P
= 0.006; Fig. 1f) but not in those patients that did not receive
genotoxic treatment (log rank P= 0.09; Supplementary informa-
tion, Fig. S1g), suggesting an important clinical role of PKM2 in
genotoxic treatment resistance.
PKM2 regulates HR-, but not NHEJ-mediated repair of DSBs
DSBs are the primary source of radiation cytotoxicity. We next
asked if PKM2 promoted treatment resistance by promoting the
repair of radiation-induced DSBs. Knockdown of PKM2 in U87 cells
resulted in an elevated basal level of DSBs, as assessed by γ-H2AX
foci (Fig. 2a), suggesting that PKM2 may be involved in managing
DSB repair resulting from oxidative stress in the absence of
radiation.12–16 Interestingly, knockdown of PKM2 did not affect
DSBs present 1 h post-irradiation, but did significantly increase the
percentage of cells with persistent DSBs remaining 16 h post-
treatment (Fig. 2a). This indicates that PKM2 confers treatment
resistance not by decreasing the amount of DNA damage incurred
as a result of treatment, but rather by encouraging repair of these
lesions after the fact.
Repair of DSBs is primarily carried out by either the NHEJ or HR-
mediated DNA repair pathways. We utilized chromosomal DSB
repair reporter assays, which specifically measure the efficiency of
NHEJ repair or HR repair of I-SceI-induced DSBs, respectively, to
examine whether PKM2 regulated either of these pathways.17,18
Silencing PKM2 had no effect on the efficiency of NHEJ-mediated
DSB repair, whereas knockdown of KU80, a positive control,
disrupted NHEJ repair in this assay (Fig. 2b). Intriguingly, knock-
down of PKM2 significantly diminished HR DSB repair efficiency
(Fig. 2c). Given the high level of homology between PKM1 and
PKM2 and therefore limited selection of shRNAs specific for either
isoform, rescue of PKM2 knockdown by a shRNA resistant PKM2
construct (rPKM2) provided the most definitive method to exclude
off-target effects from shPKM2. rPKM2 completely rescued HR DSB
repair efficiency in shPKM2 cells (Fig. 2c), demonstrating an
essential role for PKM2 in regulating this repair pathway (Fig. 2c).
PKM2 phosphorylates and activates CtIP to promote HR-mediated
DSB repair
To illuminate how PKM2 promotes HR-mediated DSB repair, we
examined if PKM2 interacted with well-known mediators of HR
repair. A number of HR repair proteins, including Brca1, Mre11,
Rad51, RPA, and CtIP, co-immunoprecipitated with PKM2 (Fig. 3a;
Supplementary information, Fig. S2a and b) in a DNA-damage
dependent manner. Given the essential role of CtIP in HR repair of
DSBs,19 we focused our analyses on PKM2’s ability to regulate CtIP
function during HR repair. First, we assessed CtIP binding to DNA
50–604 nucleotides upstream of I-SceI-induced DSBs20 (Fig. 3b).
CtIP binding to DNA flanking DSBs was increased 3-fold at 4 h
after adenoviral delivery of I-SceI and returned to basal levels by 8
h (Fig. 3b; Supplementary information, Fig. S2c). PKM2 knockdown
significantly impaired CtIP recruitment to DSBs, indicating that
PKM2 regulates this important function of CtIP.
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In addition to catalyzing the transfer of a phosphate group from
phosphoenolpyruvate (PEP) to ADP to produce pyruvate and ATP
in the cytoplasm, PKM2 functions as a nuclear protein kinase
utilizing PEP as a phosphate donor.21 Given that phosphorylation
is an important mechanism for regulating CtIP’s function,19 we
analyzed if PKM2 phosphorylated CtIP. We observed a PKM2-
dependent increase in threonine, but not tyrosine or serine
phosphorylation of CtIP in irradiated U87 cells (Supplementary
information, Fig. S2d and data not shown). To identify the
threonine residue(s) of CtIP that are phosphorylated by PKM2, we
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analyzed phosphorylation of recombinant protein fragments
covering the N-terminal (residues 45–371), middle (residues
374–649) and C-terminal (residues 650–897) portions of CtIP in
the presence of recombinant PKM2 in vitro (Supplementary
information, Fig. S2e). WT and R399E PKM2, which has increased
protein kinase activity,6 utilized PEP, but not ATP, as a phosphate
donor to phosphorylate the N-terminal region of CtIP in vitro,
while the mid-portion and the C-terminal part were not
phosphorylated (Supplementary information, Fig. S2e). We next
used a series of additional CtIP peptide fragments to narrow the
threonine residue on CtIP phosphorylated by PKM2 to the region
between residues 121 and 180 (Supplementary information,
Fig. S2f). Two threonine residues (T126 and T166) are located in
this region. We mutated each of these residues in fragment
61–274 to an alanine and found that only T126 was phosphory-
lated by PKM2 (Supplementary information, Fig. S2g and data not
shown). To confirm that CtIP was phosphorylated in a PKM2-
dependent manner on T126 following radiation, we conducted
liquid chromatography-coupled ion mass spectrometry (LC-MS/
MS) analysis of trypsin-digested fragments of Flag-CtIP over-
expressed in U87 control or shPKM2 cells with or without radiation
treatment (Fig. 3c; Supplementary information, Fig. S3a and b). LC-
MS/MS in the multiple-reaction monitoring (MRM) mode revealed
that phosphorylation of the CtIP T126-containing peptide,
NTLQEENK, was stimulated by exposure to radiation and this
stimulation was abrogated in cells after shRNA-mediated knock-
down of PKM2. To further evaluate T126 as the specific residue of
CtIP phosphorylated by PKM2 following DNA damage, we
expressed flag-tagged WT or T126A CtIP in shPKM2 U87 cells.
Radiation resulted in a significant increase in threonine phosphor-
ylation of WT but not T126A CtIP and this phosphorylation was
abrogated by knockdown of PKM2 (Fig. 3d), further confirming
T126 as the unique residue on CtIP phosphorylated by PKM2 in
response to DNA damage. Finally, to analyze PKM2-mediated
phosphorylation of T126 on endogenous CtIP in response to
radiation we utilized an antibody specific for phosphorylated T126
CtIP (Fig. 3e). A significant increase in endogenous pT126 CtIP was
observed in protein lysates harvested from cells following
radiation treatment (Fig. 3e) or treatment with the topoisomerase
I inhibitor CPT-11 (irinotecan) (Supplementary information,
Fig. S4a). Treating these lysates with λ-phosphatase significantly
reduced the intensity of the band detected by anti-pT126 CtIP
antibody following immunoblotting suggesting that this antibody
is specific for the phosphorylated protein. Furthermore, knock-
down of PKM2 significantly reduced the amount of endogenous
pT126 CtIP detected in the lysates of irradiated cells (Fig. 3e),
whereas knockdown of PKM1 did not reduce T126-CtIP phosphor-
ylation following DNA damage (Supplementary information,
Fig. S4a).
We next asked if phosphorylation of T126 by PKM2 regulated
CtIP function in HR repair. To begin, we used an in vivo
chromosome-based ssDNA resection assay to analyze CtIP-
mediated resection at I-SceI-generated DSBs (Supplementary
information, Fig. S4b). In this assay the relative amount of ssDNA
adjacent to I-SceI sites, indicative of CtIP end-resection activity, is
measured by quantitative PCR.22 Endogenous PKM2 and CtIP were
knocked down and replaced as indicated by flag-tagged versions
of WT PKM2 (rPKM2) and either WT CtIP, T126A CtIP, or
phosphomimetic T126E CtIP (Fig. 3f). In cells expressing rPKM2,
T126E CtIP fully restored ssDNA resection function relative to cells
expressing WT CtIP, whereas expression of an equivalent amount
of T126A CtIP resulted in significantly reduced ssDNA resection
(Fig. 3f, columns 1–3). Importantly, in cells lacking PKM2,
expression of phosphomimetic T126E resulted in significantly
greater resection function compared to expression of an
equivalent amount of WT CtIP, providing evidence that phosphor-
ylation of CtIP at T126 by PKM2 increases CtIP resection function
(Fig. 3f, columns 4–5). We next analyzed if phosphorylation of CtIP
T126 by PKM2 regulated HR-mediated repair of I-SceI-induced
DSBs (Fig. 3g). Similar to the results of the DNA resection assay, in
the presence of PKM2, expression of T126E restored HR repair
function to a level similar to cells expressing WT CtIP, while
expression of an equivalent amount of T126A CtIP resulted in
significantly reduced HR-mediated DSB repair (Fig. 3g, columns
1–3). Furthermore, expression of T126E CtIP in cells lacking PKM2
resulted in significantly greater HR-mediated DSB repair compared
to expression of WT CtIP (Fig. 3g, columns 4–5). These results
establish phosphorylation of CtIP at T126 by PKM2 as a critical
mechanism to activate CtIP’s function in HR-mediated DSB repair.
To further confirm a role for PKM2 in the regulation of CtIP
function, we analyzed CtIP-regulated DNA end resection by
fluorescence microscopy to visualize ssDNA-bound RPA foci and
detection of BrdU-ssDNA tracks following exposure to irinotecan
(CPT-11) (Fig. 3h, i; Supplementary information, Fig. S4c and d).
Knockdown of PKM2 significantly reduced DNA end resection as
determined by these methods.
ATM phosphorylates nuclear PKM2 leading to its retention in the
nucleus
Next, we inquired how the presence of DNA damage is signaled to
PKM2 to activate its role in DSB repair. ATM is a well-established
critical early response kinase activated in response to DNA
damage3 and T328 of PKM2 was previously identified as a
potential ATM phosphorylation site.23 We observed, via reciprocal
co-immunoprecipitation experiments, that IR induces ATM bind-
ing to PKM2, but not PKM1 (Fig. 4a). Furthermore, purified ATM
phosphorylated WT PKM2 but not T328A PKM2, while the kinase-
dead version of ATM (ATM-KD) did not phosphorylate either WT or
T328A PKM2, confirming T328 as a target residue for phosphor-
ylation by ATM (Fig. 4b). To determine if ATM phosphorylates T328
on PKM2 following DNA damage in vivo, we expressed His-tagged
WT or T328A PKM2 in 293 T cells grown in the presence of
Fig. 1 PKM2 is a critical mediator of cellular resistance to DNA-damaging treatment. a Clonogenic survival of U87 shCtrl and shPKM2 cells
following irradiation with 0 to 8 Gy. Western blot (inset) shows PKM2 expression in these cells. Results are mean ± SE (n= 3). *P < 0.05. b
Clonogenic survival of U87 cells treated with control siRNA or siRNA targeting PKM1 or PKM2 24 h prior to irradiation. Western blot (inset)
demonstrates PKM1 and PKM2 expression 24 h after siRNA treatment. Cells were irradiated as indicated. Results are mean ± SE (n= 4). *P <
0.05. c Mice bearing U87 tumors expressing shCtrl or shPKM2 were assigned to no radiation or radiation treatment (2 Gy × 5 d) groups. The
average volume for shCtrl tumors was 132.5 mm3 at the start of treatment; for shPKM2 tumors, the average volume at the start of treatment
was 137.7 mm3. shCtrl tumor reached target volume to begin treatment in 36.5 days on average while shPKM2 tumors required 44.8 days to
reach the target volume. Tumor growth was monitored for 24 d. Results are mean tumor volume relative to starting volume ± SD (6 mice/
group). *P < 0.05. d MRI images of a representative intracranial U87/EGFRvIII tumor at day 8 (upper left panel) and 15 (upper right panel). H&E
(middle and lower left panels) and Ki-67 (middle and lower right panels) staining of a day 15 tumor. e Mice were implanted with 50,000 U87/
EGFRvIII cells expressing shCtrl or shPKM2 by intracranial injection and assigned to no radiation or radiation treatment (4 Gy × 3 d) groups (see
Table for details). Mean survival for each group was calculated and survival was analyzed by the Kaplan Meier method, with comparisons
between the groups made by a log rank test (see Table). P < 0.05 was considered significant. f Patients receiving genotoxic treatment in the
TCGA GBM cohort were stratified by PKM expression (PKM High= upper 10th percentile; PKM Low= lower 90th percentile) and overall survival
was analyzed by the Kaplan Meier method (P= 0.006 for the difference between high and low expression groups)
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radiolabeled ATP. Radiation induced a significant increase in the
phosphorylation of WT but not T328A PKM2, which was prevented
by the ATM inhibitor KU55933 (Fig. 4c). Combined, these data
reveal that, in response to DNA damage, ATM phosphorylates
PKM2 on T328.
Both ATM and PKM2 shuttle between the cytoplasmic and
nuclear compartments in response to a variety of stimuli.5,24 While
the majority of PKM2 is cytoplasmic, ATM is predominantly
nuclear.25 We next investigated where DNA damage-induced
ATM-mediated phosphorylation of PKM2 occurred. Western blot
Fig. 2 PKM2 regulates HR-, but not NHEJ-mediated repair of DSBs. a U87 cells expressing shPKM2 were treated with 6 Gy, fixed, and analyzed
for γH2A.X foci at the indicated time points. Data are the mean percentage of cells with foci ± SE (n= 3). Representative photos illustrating
γH2A.X nuclear foci (red) in shCtrl and shPKM2 cells at 0, 1 and 16 h post treatment with 6 Gy. b Repair of DSBs by NHEJ was assayed using the
U87 cell line-based chromosomal reporter system containing a single integrated GFP reporter with two I-SceI target sites in inverted
orientation flanking an out of frame ATG upstream of the GFP reporter (see schematic). Cleavage by I-SceI removes the out of frame ATG,
leaving non-compatible ends. Repair of the DSB by NHEJ results in GFP translation. Cells were transfected with control siRNA or siRNAs
targeting PKM2 or KU80 and then transfected with pcDNA3.1/I-SceI. Resolution of DSBs by the NHEJ pathway was assessed by measuring the
percentage of GFP-positive cells, with knockdown of KU80 serving as a positive control for disruption of NHEJ repair. Data are mean ± SE (n=
3). c HR-specific repair of DSBs was analyzed in U87 cells modified with a stably integrated DR-GFP chromosomal reporter system (see
schematic). This system contains two differently mutated GFP genes oriented as direct repeats. The upstream repeat contains a single I-SceI
site while the downstream copy is a 5′-3′ truncated GFP fragment. Expression of I-SceI in these cells generates a DSB that, when repaired by
HR, results in expression of GFP. Cells were treated with control or PKM2-targeting shRNA and transfected with empty vector or vector
encoding shRNA-resistant PKM2 (rPKM2). After 24 h, DSBs were induced by transduction with I-SceI-encoding adenovirus and resolution of
I-SceI-induced DSBs by the HR pathway was assessed by measuring the percentage of GFP-positive cells 48 h later. Data are presented as
mean ± SE (n= 3). *P < 0.05
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analysis of cytosolic and nuclear protein fractions revealed that
phosphorylation on T328 can be detected by an antibody specific
for this phosphorylated residue (Supplementary information, Fig.
S5a) as soon as 30 min following DNA damage generated by
either radiation (Fig. 4d) or hydrogen peroxide (Supplementary
information, Fig. S5b). Phosphorylated T328 PKM2 persists in the
nucleus for up to 24 h after induction of DNA damage
(Supplementary information, Fig. S5c). Consistent with previous
Fig. 3 PKM2 phosphorylates and activates CtIP to promote HR-mediated DSB repair. a Protein lysates from unirradiated or irradiated U87 cells
were collected and immunoprecipitated with PKM2 and CtIP antibodies or anti-rabbit IgG. Immunoprecipitates and input control lysates were
analyzed by western blot. b Schematic: The I-SceI system in HT1904 cells utilized to analyze CtIP binding upstream of DSBs. ChIP primer sets
604, 152, and 50 bp from the I-SceI site were used to analyze CtIP binding. Bar chart: Cells were transfected with control or PKM2-targeting
siRNA and then I-SceI-expressing adenovirus was introduced to create DSBs. At the indicated time points, CtIP-DNA complexes were
harvested and CtIP binding sites were quantified by real-time PCR. Data show binding of CtIP at a site 152 bp from the I-SceI-induced DSB
normalized to T= 0 and are presented as mean ± SE (n= 3). c LC-MS/MS in the multiple-reaction monitoring (MRM) mode for monitoring
unmodified CtIP peptide, NTLQEENK, and the same peptide with Thr126 being phosphorylated in the irradiated sample. Selected-ion
chromatograms for monitoring the indicated transitions arising from the fragmentations of the [M+ 2 H]2+ ions of the unphosphorylated (top
left) and phosphorylated (bottom left) NTLQEENK. MS/MS for the [M+ 2 H]2+ ions of the unphosphorylated (top right) and phosphorylated
(bottom right) peptides averaged from the peaks at around 28.1 min and 25.8 min, respectively. d Protein lysates from U87 Ctrl and shPKM2
cells expressing flag-tagged WT or T126A CtIP and treated with 0 or 6 Gy radiation were immunoprecipitated with anti-flag antibody and
separated by SDS-PAGE followed by immunoblotting with flag and pan-phosphothreonine antibodies. Input protein lysates were collected
prior to immunoprecipitation. e Protein lysates from U87 cells treated with 0 or 6 Gy radiation were immunoprecipitated with anti-CtIP
antibody and separated by SDS-PAGE followed by immunoblotting with pT126 CtIP and total CtIP antibodies. Input protein lysates were
collected prior to immunoprecipitation. Lysates from U87 cells treated with 6 Gy were also pre-treated with λ-phosphatase prior to
immunoprecipitation with anti-CtIP antibody to demonstrate specificity of the pT126 CtIP antibody for the phosphorylated protein. Input
protein lysates were collected prior to immunoprecipitation. f HT1904 cells containing the I-SceI DSB system were utilized to analyze DNA
end-resection adjacent to I-SceI-induced DSBs. Endogenous CtIP and PKM2 were knocked down and replaced with WT, T126A, or T126E CtIP
and PKM2 as indicated. After 24 h, DSBs were induced by adenoviral delivery of I-SceI. Genomic DNA was isolated 4 h later and ssDNA
adjacent to I-SceI-induced DSBs was quantitated by quantitative real-time PCR. Data are presented as mean ± SE (n= 3). g Endogenous CtIP
and PKM2 were knocked down by siRNA or shRNA, respectively, in U87 DR-GFP cells and replaced by WT, T126A, or T126E CtIP and PKM2 as
indicated. After 24 h, DSBs were induced by adenoviral delivery of I-SceI and the ability of cells to resolve DSBs by the HR pathway was
assessed by measuring the percentage of GFP-positive cells 48 h later. Data are presented as mean ± SE (n= 3). *P < 0.05. NS, not significant.
h PKM2 or CtIP was knocked down in U87 cells by siRNA. Cells were then treated with DMSO or 2 µM CPT-11 for 1 h then stained with
antibodies against phosphoS4/S8-RPA32. Cells with > 10 foci were considered positive. i PKM2 or CtIP were knocked down in U87 cells by
siRNA. Cells were treated with BrdU (10mg/mL) for 16 h and then with DMSO or CPT-11 (2 µM) for 1 h prior to fixation. Cells with > 10 foci
were considered positive
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Fig. 4 ATM phosphorylates nuclear PKM2 leading to its retention in the nucleus. a Protein lysates from U87 cells treated with 0 or 6 Gy were
immunoprecipitated with antibodies against ATM, PKM2, or anti-rabbit IgG. Immunoprecipitates and protein input control lysates
were separated by SDS-PAGE and then immunoblotted with the indicated antibodies. b Recombinant GST-tagged WT or T328A PKM2 were
incubated with isolated ATM or a kinase-dead ATM (ATM-KD) in the presence of [γ-32P]ATP. Proteins were separated by SDS-PAGE, and 32P-
radiolabeled PKM2 was visualized using a PhosphorImager while PKM2 and ATM were detected by immunobloting. c His-tagged WT or T328A
PKM2 was expressed in 293 T cells incubated in media containing [γ-32P]ATP for 4 h prior to exposure to 6 Gy. KU55933 (20 µM) was introduced
1 h prior to radiation. Lysates were collected 1 h after irradiation and resolved by SDS-PAGE, and radiolabeled proteins were visualized by
PhosphorImager. His-tagged PKM2 was detected by immunoblotting. d U87 cells were treated with 6 Gy radiation and cell lysates were
collected at the indicated time points and separated into nuclear and cytoplasmic fractions, which were resolved by SDS-PAGE and probed
with the indicated antibodies. Superscripts 1 and 2 identify respective membranes used for immunoblotting. e U87 cells expressing flag-
tagged WT or K433R PKM2 were treated with 0 or 6 Gy radiation. Cell lysates were collected 45min after treatment and separated into nuclear
and cytoplasmic fractions, which were resolved by SDS-PAGE and probed with antibodies as indicated. Cytosolic and nuclear fractions were
also subjected to co-immunoprecipitation with anti-flag antibody prior to being resolved by SDS-PAGE and probed with antibodies against
pT328-PKM2 and Flag. f U87 cells were treated with DMSO or KU55933 (20 µM) prior to irradiation. At the indicated time points, cells were
fixed and PKM2 localization was determined by immunohistochemical staining. Photographs represent typical nuclear localization of
PKM2 seen following exposure to radiation, which is prevented by KU55933. Data are presented as the mean percentage of cells with nuclear
PKM2 staining ± SE (n= 3). g U87 shPKM2 cells were transfected with shRNA-resistant WT or T328A PKM2, and then treated with DMSO or
KU55933 (20 µM) prior to irradiation as indicated. Cells were fixed and PKM2 localization was determined by immunohistochemical staining.
Data are presented as the mean percentage of cells with nuclear PKM2 staining ± SE (n= 3). *P < 0.05. ns, not significant
PKM2 promotes resistance to genotoxic therapy
S. T. Sizemore et al.
1096
Cell Research (2018) 28:1090 – 1102
reports,26–28 we observed an increase in S1981-phosphorylated
ATM levels in the nucleus following radiation and hydrogen
peroxide treatment (Fig. 4d; Supplementary information, Fig. S5b).
Importantly, pT328 PKM2 is only detected in the nucleus,
suggesting that phosphorylation of PKM2 by ATM is a nuclear
event. To confirm that phosphorylation of PKM2 by ATM occurred
in the nucleus, we analyzed the phosphorylation of flag-tagged
WT PKM2 or a nuclear translocation-deficient mutant PKM2
(K433R).6 While phosphorylation of WT PKM2 at T328 was
observed in nuclear protein fractions and increased in response
to radiation, K433R PKM2 was confined to the cytoplasm and T328
phosphorylation of K433R PKM2 even following radiation was not
detected (Fig. 4e; Supplementary information, Fig. S5d). Combined
these data suggest that ATM phosphorylates PKM2 in the nucleus.
Interestingly, we also observed that T328 phosphorylation is
associated with PKM2 nuclear accumulation (Fig. 4d, e). Given that
PKM2 promotes HR repair of DSBs by phosphorylating CtIP, a
primarily nuclear protein,29 we hypothesized that ATM-mediated
phosphorylation of PKM2 regulated PKM2’s nuclear accumulation.
In support of this hypothesis, PKM2 (Supplementary information,
Fig. S6a-d), but not PKM1 (Supplementary information, Fig. S6c
and d), accumulated in the nucleus following radiation as
determined by both immunofluorescence staining and western
blot analysis of nuclear and cytoplasmic protein fractions. This
accumulation was significantly prevented by the ATM inhibitor
KU55933 (Fig. 4f; Supplementary information, Fig. S6d). Further-
more, T328A PKM2 failed to accumulate in the nucleus after
radiation, and KU55933 had no effect on its localization (Fig. 4g;
Supplementary information, Fig. S6e), illustrating that nuclear
accumulation of PKM2 following radiation requires phosphoryla-
tion of T328 by ATM. T328A PKM2 accumulated in the nucleus in a
similar manner to WT PKM2 following EGF stimulation which has
previously been demonstrated to be dependent upon S37 of
PKM26 (Supplementary information, Fig. S6f), illustrating that
T328A PKM2 was capable of nuclear accumulation in response to
stimuli other than DNA damage. Combined, these data support a
model in which ATM phosphorylates PKM2 in the nucleus, leading
to its nuclear accumulation and increased repair of DNA damage
resulting from genotoxic treatments.
ATM-dependent phosphorylation of PKM2 on T328 regulates
PKM2’s capacity to activate of CtIP and HR repair
We next asked if phosphorylation of T328 by ATM was necessary
for the interaction of PKM2 with CtIP. Endogenous PKM2 was
replaced in U87 cells by flag-tagged WT, T328A, or T328E PKM2. In
the absence of radiation, minimal interaction was detected
between WT PKM2 and CtIP, and no binding between T328A
PKM2 and CtIP was detected (Fig. 5a). In contrast, significantly
more T328E PKM2, compared to WT PKM2, was found in complex
with CtIP in the absence of radiation (Fig. 5a). Radiation
Fig. 5 ATM phosphorylation of PKM2 on T328 regulates PKM2’s activation of CtIP and HR repair. a shRNA-resistant, flag-tagged WT, T328A or
T328E PKM2 were expressed in U87 shPKM2 cells. Cells were irradiated, and cell lysates were collected and immunoprecipitated with
antibodies against CtIP or Flag. Immunoprecipitates and input protein lysates were resolved by SDS-PAGE, and then probed with the indicated
antibodies. exo/endo, exogenously or endogenously expressed PKM2. b shRNA-resistant WT or T328A PKM2 was expressed in U87 shPKM2
cells along with flag-tagged WT or T126A CtIP as indicated. Cells were treated with 0 or 6 Gy, and cell lysates were collected and
immunoprecipitated with anti-flag antibody. Immunoprecipitates and input lysates were resolved by SDS-PAGE, then probed with the
indicated antibodies. exo/endo, exogenously or endogenously expressed PKM2. c HT1904 cells containing the I-SceI DSB system were used to
analyze DNA end-resection adjacent to I-SceI-induced DSBs. Endogenous CtIP and PKM2 were knocked down and replaced with WT, T126A
(A), or T126E (E) CtIP and WT or T328A (A) PKM2 as indicated. DSBs were induced by adenoviral delivery of I-SceI. Genomic DNA was isolated,
and ssDNA adjacent to I-SceI-induced DSBs was quantitated by quantitative real-time PCR. Data are presented as mean ± SE (n= 3).
d Endogenous CtIP and PKM2 were knockdown by siRNA or shRNA in U87 DR-GFP cells and replaced by WT, T126A (A) or T126E CtIP (E) and
WT or T328A (A) PKM2. DSBs were induced by adenoviral delivery of I-SceI, and the ability of cells to resolve DSBs by the HR pathway was
assessed by the percentage of GFP-positive cells 48 h later. Data are presented as mean ± SE (n= 3). *P < 0.05. ns, not significant
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significantly increased the interaction of WT PKM2 with CtIP, but
had no effect on the interaction of either T328A or T328E PKM2
with CtIP (Fig. 5a). In addition, KU55933 reduced the association of
PKM2 and CtIP by greater than 2.5-fold after irradiation
(Supplementary information, Fig. S7a). Next, we determined if
ATM-dependent phosphorylation of PKM2 on T328 is required for
PKM2 to phosphorylate CtIP on T126. Endogenous PKM2 and CtIP
were knocked down in U87 cells and replaced by flag-tagged WT
or T328A PKM2 and WT or T126A CtIP. Irradiation resulted in a
significant increase in CtIP phosphorylation that was dependent
upon the presence of both T328 on PKM2 and T126 on CtIP
(Fig. 5b). Together, these results reveal that phosphorylation of
PKM2 on T328 by ATM following DNA damage is required for
PKM2 to form a complex with and phosphorylate CtIP on T126.
To better understand the extent to which the ATM-PKM-CtIP
axis contributes to the PKM2-mediated increase in DSB repair, we
analyzed the resection efficiency of I-SceI-induced DSBs in HT1904
cells in which endogenous PKM2 and CtIP were both knocked
Fig. 6 The ATM-PKM2-CtIP axis provides resistance to genotoxic agents. a U87 shCtrl and shPKM2 cells, and shPKM2 cells expressing shRNA-
resistant WT or T328A PKM2, were irradiated with 6 Gy. The number of viable cells was determined by trypan blue staining at the indicated
time points. Data are the relative mean fraction of surviving cells ± SE (n= 3). b WT or T328E PKM2 was overexpressed in U87 cells. Cells were
pre-treated with DMSO or 10 µM KU55933 and then irradiated. The number of viable cells was determined by trypan blue staining at the
indicated time points. Data are the relative mean fraction of surviving cells ± SE (n= 3). c U87 shCtrl or shPKM2 cells, and shPKM2 cells
overexpressing WT or T126E CtIP, were irradiated and the number of viable cells was determined by trypan blue staining at the indicated time
points. Data are the relative mean fraction of surviving cells ± SE (n= 3). d U87 shCtrl or shPKM2 cells, and shPKM2 cells expressing shRNA-
resistant WT, T328A, or T328E PKM2 were incubated with the indicated concentrations of olaparib. Cell viability was determined by trypan
blue staining 48 h after treatment. Data are the relative mean fraction of surviving cells ± SE (n= 3). e Representative 10 × and 40 × images
from GBM patient samples exhibiting high (left panels) or low (right panels) staining for pT328-PKM2. f The GBM patient cohort (n= 104) was
separated into two groups along the median pT328-PKM2 H-score. Survival was analyzed by the Kaplan Meier method. Statistical differences
in overall survival between the groups were determined by the log rank test (P= 0.04). *P < 0.05
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down and replaced with WT or T328A PKM2 and WT, T126A, or
T126E CtIP. Replacing either WT PKM2 with T328A PKM2 or WT
CtIP with T126A CtIP significantly impaired resection (Fig. 5c,
columns 2–3 versus column 1; Supplementary information,
Fig. S7b). Replacing both WT PKM2 and WT CTIP with T328A
PKM2 and T126A CtIP did not further reduce resection efficiency
compared to cells in which only one of these proteins was
mutated (column 4 versus columns 2–3), suggesting they function
in the same pathway. Furthermore, resection function was not
significantly different between cells expressing WT or T328A PKM2
when phosphomimetic T126E CtIP was expressed (columns 5–6),
demonstrating that phosphorylation of T126 on CtIP by PKM2 is
important for CtIP function. Similar results were found in
complementary assays measuring HR-mediated repair of I-SceI-
induced DSBs (Fig. 5d; Supplementary information, Fig. S7c).
Furthermore, KU55933 significantly decreased HR repair in cells
expressing WT PKM2, but had no significant effect on HR-
mediated repair in cells expressing the T328A or T328E PKM2
mutants (Supplementary information, Fig. S7d). Additionally, cells
expressing T328E PKM2 retained a significantly greater portion of
their HR repair function following KU55933 treatment than those
expressing WT PKM2 (Supplementary information, Fig. S7d). Taken
together, these data demonstrate that ATM-mediated phosphor-
ylation of PKM2 at T328 is prerequisite for PKM2 to phosphorylate
CtIP on T126 and increase HR repair of DSBs.
The ATM-PKM2-CtIP axis provides resistance to genotoxic agents
Our results thus far have established an important novel function
of PKM2 in regulating HR-mediated DSB repair. We next asked if
signaling through the newly discovered ATM-PKM2-CtIP repair
axis rendered cancer cells resistance to a variety of genotoxic
agents. First, endogenous PKM2 was knocked down in U87 cells
and replaced by WT or T328A PKM2 (Supplementary information,
Fig. S8a). These cells were subjected to 6 Gy radiation and
monitored for survival over 7 days (Fig. 6a). As expected,
knockdown of PKM2 significantly decreased survival, which could
be partially, but significantly, rescued by expression of exogenous
WT PKM2. Conversely, T328A PKM2 expressed at a similar level
(Supplementary information, Fig. S8a) not only did not rescue
survival in PKM2 knockdown cells but further reduced survival.
Since T328 is the target site for phosphorylation by ATM on
PKM2, we next tested if KU55933 sensitized U87 cells to radiation
treatment and if this sensitization could be reversed by expression
of phosphomimetic T328E PKM2. As expected, KU55933 sensitized
U87 cells expressing WT PKM2 to 6 Gy radiation (Fig. 6b).
Replacing WT PKM2 with T328E PKM2 expressed at a similar level
(Supplementary information, Fig. S8a) significantly increased cell
survival after treatment (Fig. 6b). Given that PKM2 regulates HR
repair of DSBs by activating CtIP through phosphorylation of T126,
we next asked if expression of phosphomimetic T126E CtIP could
restore treatment resistance in PKM2 knockdown cells. While
overexpression of WT CtIP conferred some resistance to radiation
treatment in PKM2 knockdown cells, expression of an equivalent
amount of T126E CtIP (Supplementary information, Fig. S8b)
provided significantly greater resistance (Fig. 6c). Collectively,
these results demonstrate that the ATM-PKM2(T328)-CtIP(T126)
axis is a significant contributor to cancer cell resistance to DNA-
damaging therapies.
HR-mediated DSB repair deficiency in cancer cells can create a
synthetic lethality to PARP inhibitors (PARPi). We found that
knockdown of PKM2 increased sensitivity of U87 (Fig. 6d) and
U251 (Supplementary information, Fig. S8c) to the PARPi olaparib.
Overexpression of either WT or T328E PKM2 rescued U87 and
U251 shPKM2 cells from PARPi synthetic lethality, whereas T382A
expression actually increased the sensitivity of PKM2 knockdown
cells to PARPi. Additional experiments in which U87 cells were
subjected to a range of radiation doses from 0 to 6 Gy
(Supplementary information, Fig. S8d), treated with the
topoisomerase I inhibitor CPT-11 (irinotecan) to induce DNA
damage (Supplementary information, Fig. S8e and f), or with
hydrogen peroxide (Supplementary information, Fig. S8g) to
produce oxidative stress confirmed that exogenous WT
PKM2 significantly rescued survival in PKM2 knockdown cells
while equivalent expression of T328A PKM2 further impaired
survival.
Finally, we asked if ATM-dependent phosphorylation of PKM2 at
T328 was prognostic of GBM patient clinical outcome. We stained
a cohort of GBM tumors with antibodies against pS1981-ATM and
pT328-PKM2 (Supplementary information, Fig. S9a). Interestingly,
even though these samples were taken from patients prior to
therapy, we found a significant correlation (P= 0.005) between
pS1981-ATM and nuclear pT328-PKM2 staining (Supplementary
information, Fig. S9b), which may reflect an important role for this
pathway in coping with increased oxidative stress within the
tumor environment. Importantly, elevated nuclear pT328-PKM2
was significantly prognostic of worse overall survival (log rank P=
0.04; Fig. 6e, f) suggesting that activation of this pathway might
identify tumors that are primed for resistance to genotoxic
therapies.
DISCUSSION
Glucose metabolism and DNA repair are two fundamental cellular
processes frequently dysregulated in cancer. Metabolic pathways
provide cells with nucleic acids and energy required to repair DNA.
As such, it is not surprising that crosstalk exists to coordinate these
two essential networks.8,30 However, until now, the connections
between the metabolic and DNA repair circuitries have been
limited. We show that PKM2, the key enzyme of glycolysis, is a
direct target for phosphorylation by ATM. Importantly, this
phosphorylation event is essential for PKM2’s retention in the
nucleus, where PKM2 phosphorylates CtIP, one of the principal
components of HR repair, creating a novel direct connection
between glycolytic metabolism and DNA repair.
PKM2’s function as a threonine and tyrosine protein kinase has
been demonstrated in a number of previous reports. Yang et al.
initially demonstrated that phosphorylation of histone H3 at T11
directly by PKM2 facilitates the dissociation of HDAC3 from the
promoters of β-catenin target genes.31 PKM2 has also been reported
to phosphorylate STAT3 at Y705, thereby enhancing its transcrip-
tional activity.16 More recently, PKM2 has been found to phosphor-
ylate H2AX,32 PAK2,33 and SNAP-23.34 While the ability of PKM2 to
directly phosphorylate proteins has been challenged,35 unbiased
proteomic screens have identified over 900 substrates for PKM2.36,37
Our work establishes PKM2 as a novel upstream regulator of CtIP
and its direct phosphorylation of CtIP on T126 as an important
mechanism of activation of CtIP-associated DSB end-resection and
subsequent HR-mediated DSB repair. None the less, as pointed out
by Lu and Hunter,38 some skepticism of PKM2’s function as a protein
kinase must remain until such time that a crystal structure of PKM2
bound to a substrate is achieved to clearly demonstrate how a
target residue in the substrate is presented to the active site in PKM2
to accommodate phosphate transfer.
CtIP activity is regulated by a variety of kinases involved in the
DNA damage response, suggesting maximal CtIP activity requires
positive input from multiple pathways.39 One example of the
coordinated activation of CtIP by multiple inputs is the finding by
Wang et al. that CDK-dependent phosphorylation of CtIP is
prerequisite for phosphorylation of CtIP by ATM and maximal end-
resection following DNA damage.19 Our results suggest that
maximal activation of CtIP in the models utilized by this study
requires PKM2 activation by ATM. ATM-regulated PKM2-mediated
activation of CtIP may represent a means for highly proliferative
cancer cells to accentuate this repair mechanism and may be one
of the important mechanisms through which these cells manage
increased oxidative stress. How phosphorylation of T126
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influences other posttranslational modifications of CtIP will be the
focus of future studies.
PKM2 is a cytoplasmic–nuclear shuttling protein, and the
regulatory mechanisms for PKM2 trafficking have been well
characterized40 beginning with Yang et al.’s demonstration that
phosphorylation of S37 on PKM2 by ERK1/2 is required for
translocation of PKM2 to the nucleus in response to EGFR
signaling.6 A number of additional post-translational modifications
to PKM2, including SUMOylation by PIAS341 and acetylation by the
p300 acetyltransferase42, have also been demonstrated to
facilitate its nuclear translocation. We show that phosphorylation
of PKM2 T328 by ATM occurs in the nucleus and is critical for
PKM2’s nuclear retention following DNA damage. Nuclear reten-
tion of PKM2 is required for its interaction with and activation of
CtIP, although the absolute requirement of pT328-PKM2 for this
interaction cannot yet be concluded. Whether other mechanisms
are activated following DNA damage that increase PKM2 transport
into the nucleus, the precise mechanisms through which
phosphorylation of PKM2 on T328 keeps PKM2 in the nucleus,
and the detailed mechanism of PKM2-CtIP interaction will be the
subject of future studies.
Recently, PKM2 was found to be phosphorylated on T328 by
GSK-3β and this phosphorylation was critical for the stability and
biological function of PKM2 in hepatocellular carcinoma.43 GSK3β
is a cytoplasmic-nuclear shuttling protein that is active in the
nucleus following DNA damage.44 Therefore, we cannot rule out
that in addition to ATM, GSK3β may also phosphorylate nuclear
PKM2 in response to DNA damage. However, active GSK3β
generally promotes cell death rather than DNA repair, whereas
inhibition of GSk3β enhances DSB repair.45 Furthermore, activity of
nuclear GSK3β was recently shown to be attenuated by ATM
through p38 to promote repair of DSBs.46 As such, it is unlikely
that GSK3β plays a significant role, relative to ATM, in
phosphorylation of T328 PKM2 following DNA damage.
Overexpression of PKM2 is a trait shared by the majority of
cancers and this PK isoform is critical for cancer metabolic
reprograming via its functions as a pyruvate kinase in the cytosol
and a protein kinase and transcriptional coactivator in the
nucleus.40 Our data revealed an unexpected role of nuclear
PKM2 in promoting HR-mediated repair of DNA damage,
positioning PKM2 at the convergence of metabolic reprograming
and DNA repair (Fig. 7). The findings presented herein promote
the development of PKM2-targeted therapies not only as a means
to target cancer metabolism, but more importantly to inhibit an
essential mechanism of cancer cell resistance to genotoxic
damage. Strategies that combine PKM2 inhibition with genotoxic
agents may more effectively take advantage of this apparent
Achilles’ heel in cancer.
MATERIALS AND METHODS
Cell survival assays
Cell survival was analyzed by colony formation as described
previously47 or by trypan blue staining of viable cells.
In vivo tumor models
All animal procedures were approved by the Institutional Animal
Care and Use Committee at The Ohio State University. U87 cells
Fig. 7 PKM2 is over-expressed in cancer where it unites cancer glycolytic metabolism with DNA repair to drive treatment resistance. PKM2 is
frequently overexpressed in cancer cells where cytosolic PKM2 reprograms glucose metabolism (Warburg effect), while nuclear PKM2 has
additional oncogenic function as a transcriptional coactivator (black arrows). Our data uncovered a novel nuclear function of PKM2 through
which it directly regulates DNA DSB repair and resistance to genotoxic damage (red arrows). ATM, activated by DNA DSBs, phosphorylates
nuclear PKM2 at T328, resulting in nuclear retention and accumulation of PKM2. pT328-PKM2 interacts with CtIP and phosphorylates CtIP on
T126 to increase its function in HR repair, resulting in increased DSB repair efficiency and resistance to genotoxic treatments
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(2.5 × 106) expressing shCtrl and shPKM2 were subcutaneously
injected into the flanks of 6–8 week old female athymic nu/nu
mice (Charles River). Mice were randomly assigned to control or
radiation treatment (2 Gy × 5 consecutive days) arms when the
volume of their tumor exceeded 100 mm3. Tumor volume was
monitored until removal criteria for the study were reached, at
which point the animal was sacrificed. Survival was studied in
mice bearing intracranial U87/EGFRvIII tumors expressing shCtrl or
shPKM2, which grew from 50,000 cells stereotactically implanted
into the brains of 6–8 week old female athymic nu/nu mice. Mice
were imaged by MRI on days 8 and 15 after implantation to
monitor the presence of tumors. On day 15, mice with confirmed
intracranial tumors were randomly assigned to control or radiation
treatment (4 Gy × 3 consecutive days) groups. Mice were sacrificed
when they became moribund.
Nonhomologous end-joining (NHEJ) repair assay
The system used to measure NHEJ repair of I-SceI-induced DSBs
has been described previously.17 Briefly, pEJ is an NHEJ-dependent
GFP-reporter assay stably integrated into the genome of the U87
cells. GFP translation is prevented in this reporter by the presence
of an out-of-frame ATG in the 5′-untranslated region between the
CMV promoter and the GFP open reading frame. Two repeated I-
SceI sites in inverted orientation flank this out-of-frame ATG.
Cleavage by I-SceI removes the out-of-frame ATG and creates non-
cohesive double-stranded ends. Repair of this DSB by NHEJ results
in GFP translation, which was measured by flow cytometry
(FACSort, Becton-Dickinson).
Homologous recombination repair assay
The DR-GFP reporter system used to determine repair of I-SceI-
induced DSBs via HR has been described previously.18 We
transfected the DR-GFP plasmid into human U87 glioma cells
and established a stably transfected clone by selection with
puromycin (5 μg/mL). Briefly, this reporter contains a cassette of
two differently mutated GFP genes in direct repeat. One repeat
contains a single I-SceI site, while the other copy is a truncated
GFP fragment. I-SceI generates a DSB that, if repaired by HR,
results in a complete GFP open reading frame. Translation of GFP
was measured by flow cytometry (FACSort, Becton-Dickinson).
CtIP chromatin immunoprecipitation
HT1904 cells containing the I-SceI DSB system and its use to
analyze protein binding upstream of I-SceI-induced DSBs have
been described previously.48 ChIP was performed per the
manufacturer’s recommendations using a Chromatin Immunopre-
cipitation Assay Kit (Millipore), anti-CtIP antibody (Active Motif)
and primers targeting sites 604, 152, and 50 bp upstream from the
I-SceI site (see Supplemental information, Data S1).
Statistical analyses
Statistical analyses were performed using Winstat or Excel. Unless
otherwise noted, statistical analysis between groups was per-
formed by ANOVA and direct comparisons between two groups
were done by a two-tailed t-test. P < 0.05 was considered
statistically significant.
ACKNOWLEDGEMENTS
We gratefully acknowledge Dr. Robert Hromas (University of New Mexico Cancer
Center), Dr. Zhi-Ren Liu (Georgia State University), Dr. Xiaohua Wu (The Scripps
Research Institute), Dr. Stephen P. Jackson (Department of Biochemistry, University of
Cambridge) and Dr. Henning Willers (Department of Radiation Oncology, Massachu-
setts General Hospital, Harvard Medical School) for providing essential reagents. We
also thank Dr. Cynthia Timmers of The Ohio State University’s Solid Tumor
Translational Science Shared Resource for her expertise. This study was supported
by the NIH grant R01 CA188500 to F.X. and A.C. and R01 CA163838 to F.X.
AUTHOR CONTRIBUTIONS
F.X., A.C., S.T.S, M.Z. and J.H.C. conceived and designed the experiments. S.T.S, M.Z., J.
H.C, G.M.S., and B.H. performed the experiments. F.X., S.T.S., M.Z., and J.H.C. analyzed
the data. B.K., N.L.L., M.C.O., and P.A.R. provided essential reagents. S.T.S. and F.X.
wrote the manuscript. All authors reviewed and approved the manuscript for
publication.
ADDITIONAL INFORMATION
Supplementary information accompanies this paper at https://doi.org/10.1038/
s41422-018-0086-7.
Competing interests: The authors declare no competing interests.
REFERENCES
1. Mao, P. et al. Homologous recombination-dependent repair of telomeric DSBs in
proliferating human cells. Nat. Commun. 7, 12154–12165 (2016).
2. Karanam, K., Kafri, R., Loewer, A. & Lahav, G. Quantitative live cell imaging reveals
a gradual shift between DNA repair mechanisms and a maximal use of HR in mid
S phase. Mol. Cell 47, 320–329 (2012).
3. Shiloh, Y. & Ziv, Y. The ATM protein kinase: regulating the cellular response to
genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 14, 197–210 (2013).
4. Sartori, A. A. et al. Human CtIP promotes DNA end resection. Nature 450, 509–514
(2007).
5. Yang, W. & Lu, Z. Nuclear PKM2 regulates the Warburg effect. Cell Cycle 12,
3154–3158 (2013).
6. Yang, W. et al. ERK1/2-dependent phosphorylation and nuclear translocation of
PKM2 promotes the Warburg effect. Nat. Cell Biol. 12, 1295–1304 (2012).
7. Anastasiou, D. et al. Inhibition of pyruvate kinase M2 by reactive oxygen species
contributes to cellular antioxidant responses. Science 334, 1278–1283 (2011).
8. Efimova, E. V. et al. Linking cancer metabolism to DNA repair and accelerated
senescence. Mol. Cancer Res. 14, 173–184 (2016).
9. Kefas, B., Comeau, L., Erdle, N., Montgomery, E., Amos, S. & Purow, B. Pyruvate
kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the
survival of glioma cells. Neuro. Onco. 12, 1102–1112 (2010).
10. Stupp, R., Hegi, M. E., Gilbert, M. R. & Chakravarti, A. Chemoradiotherapy in
malignant glioma: standard of care and future directions. J. Clin. Oncol. 25,
4127–4136 (2007).
11. Desai, S. et al. Tissue-specific isoform switch and DNA hypomethylation of the
pyruvate kinase PKM gene in human cancers. Oncotarget 5, 8202–8210 (2014).
12. Lee, A. Y., Liu, E. & Wu, X. The Mre11/Rad50/Nbs1 complex plays an important
role in the prevention of DNA r replication in mammalian cells. J. Biol. Chem. 282,
32243–32255 (2007).
13. Wang, H. et al. CtIP protein dimerization is critical for its recruitment to chro-
mosomal DNA double-stranded breaks. J. Biol. Chem. 287, 21474–21480 (2012).
14. Li, Z., Yang, J. & Huang, H. Oxidative stress induced H2AX phosphorylation in
human spermatozoa. FEBS Lett. 580, 6161–6168 (2006).
15. Venkatachalam, G., Surana, U. & Clement, M. V. Replication stress-induced
endogenous DNA damage drives cellular senescence induced by a sub-lethal
oxidative stress. Nucleic Acids Res. 45, 10564–10582 (2017).
16. Lemon, J. A., Rollo, C. D. & Boreham, D. R. Elevated DNA damage in a mouse
model of oxidative stress: impacts of ionizing radiation and a protective dietary
supplement. Mutagenesis 23, 473–482 (2008).
17. Wu, Y. et al. EEPD1 Rescues stressed replication forks and maintains genome
stability by promoting end resection and homologous recombination repair.
PLoS. Genet. 11, e1005675 (2015).
18. Makharashvili, N. et al. Catalytic and noncatalytic roles of the CtIP endonuclease
in double-strand break end resection. Mol. Cell 54, 1022–1033 (2014).
19. Wang, H. et al. The interaction of CtIP and Nbs1 connects CDK and ATM to
regulate HR-mediated double-strand break repair. PLoS. Genet. 9, e1003277 (2013).
20. Hromas, R. et al. Chk1 phosphorylation of Metnase enhances DNA repair but
inhibits replication fork restart. Oncogene 31, 4245–4254 (2012).
21. Gao, X., Wang, H., Yang, J. J., Liu, X. & Liu, Z. R. Pyruvate kinase M2 regulates gene
transcription by acting as a protein kinase. Mol. Cell 45, 598–609 (2012).
22. Zhou, Y., Caron, P., Legube, G. & Paull, T. T. Quantitation of DNA double-strand
break resection intermediates in human cells. Nucleic Acids Res. 42, e19 (2014).
23. Matsuoka, S. et al. ATM and ATR substrate analysis reveals extensive protein
networks responsive to DNA damage. Science 316, 1160–1166 (2007).
24. Yang, W. & Lu, Z. Pyruvate kinase M2 at a glance. J. Cell. Sci. 128, 1655–1660
(2015).
25. Gately, D. P., Hittle, J. C., Chan, G. K. & Yen, T. J. Characterization of ATM
expression, localization, and associated DNA-dependent protein kinase activity.
Mol. Biol. Cell. 9, 2361–2374 (1998).
PKM2 promotes resistance to genotoxic therapy
S. T. Sizemore et al.
1101
Cell Research (2018) 28:1090 – 1102
26. Yang, Y. et al. Cell cycle stage-specific roles of Rad18 in tolerance and repair of
oxidative DNA damage. Nucleic Acids Res. 41, 2296–2312 (2013).
27. Kozlov, S. V., Graham, M. E., Peng, C., Chen, P., Robinson, P. J. & Lavin M. F.
Involvement of novel autophosphorylation sites in ATM activation. EMBO J. 25,
3504–3514 (2006).
28. Golding, S. E., Rosenberg, E., Neill, S., Dent, P., Povirk, L. F. & Valerie K. Extracellular
signal-related kinase positively regulates ataxia telangiectasia mutated, homo-
logous recombination repair, and the DNA damage response. Cancer Res. 67,
1046–1053 (2007).
29. Yu, X. & Baer, R. Nuclear localization and cell cycle-specific expression of CtIP, a
protein that associates with the BRCA1 tumor suppressor. J. Biol. Chem. 275,
18541–18549 (2000).
30. Mims, J. et al. Energy metabolism in a matched model of radiation resistance for
head and neck squamous cell cancer. Radiat. Res. 183, 291–304 (2015).
31. Yang, W. et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR
activation. Nature 480, 118–122 (2011).
32. Xia, L. et al. Pyruvate kinase M2 phosphorylates H2AX and promotes genomic
instability in human tumor cells. Oncotarget 8, 109120–109134 (2017).
33. Cheng, T. Y. et al. Pyruvate kinase M2 promotes pancreatic ductal adenocarci-
noma invasion and metastasis through phosphorylation and stabilization of PAK2
protein. Oncogene 37, 1730–1742 (2018).
34. Wei, Y. et al. Pyruvate kinase M2 promotes tumour cell exosome release via
phosphorylating synaptosome-associated protein 23. Nat. Commun. 8,
14041–14053 (2017).
35. Hosios, A. M, Fiske, B. P., Gui, D. Y. & Vander Heiden, M. G. Lack of evidence for
PKM2 protein kinase activity. Mol. Cell 59, 850–857 (2015).
36. Keller, K. E., Doctor, Z. M., Dwyer, Z. W. & Lee, Y. S. SAICAR induces protein kinase
activity of PKM2 that is necessary for sustained proliferative signaling of cancer
cells. Mol. Cell 53, 700–709 (2014).
37. He, C. L. et al. Pyruvate knase M2 activates mTORC1 by phosphorylating AKT1S1.
Sci. Rep. 6, 1524–1538 (2016).
38. Lu, Z. & Hunter, T. Metabolic kinases moonlighting as protein kinases. Trends
Biochem. Sci. 43, 301–310 (2018).
39. Makharashvili, N. & Paull, T. T. CtIP: a DNA damage response protein at the
intersection of DNA metabolism. Dna. Repair. (Amst.). 32, 75–81 (2015).
40. Yang, W. & Lu, Z. Regulation and function of pyruvate kinase M2 in cancer. Cancer
Lett. 339, 153–158 (2013).
41. Spoden, G. A. et al. The SUMO-E3 ligase PIAS3 targets pyruvate kinase M2. J. Cell.
Biochem. 107, 293–302 (2009).
42. Lv, L. et al. Mitogenic and oncogenic stimulation of K433 acetylation promotes
PKM2 protein kinase activity and nuclear localization. Mol. Cell 52, 340–352
(2013).
43. Xu, Q. et al. HSP90 promotes cell glycolysis and inhibits apoptosis by regulating
PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma. Mol.
Cancer 16, 178–193 (2017).
44. Watcharasit, P., Bijur, G. N., Song, L., Zhu, J., Chen, X. & Jope, R.S. Glycogen
synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J.
Biol. Chem 278, 48872–48879 (2003).
45. Yang, E. S., Nowsheen, S., Wang, T., Thotala, D. K. & Xia, F. Glycogen synthase
kinase 3beta inhibition enhances repair of DNA double-strand breaks in irra-
diated hippocampal neurons. Neuro. Oncol. 13, 459–470 (2011).
46. Thornton, T. M. et al. Inactivation of nuclear GSK3B by Ser(389) phosphorylation
promotes lymphocyte fitness during DNA double-strand break response. Nat.
Commun 7, 10553–10565 (2016).
47. Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic
assay of cells in vitro. Nat. Protoc. 1, 2315–2319 (2006).
48. Fnu, S. et al. Methylation of histone H3 lysine 36 enhances DNA repair by non-
homologous end-joining. Proc. Natl. Acad. Sci. U. S. A. 108, 540–545 (2011).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2018
PKM2 promotes resistance to genotoxic therapy
S. T. Sizemore et al.
1102
Cell Research (2018) 28:1090 – 1102
